

関節リウマチ (RA)

Drug: ABT-122

Condition: RA

Title: A study to investigate the safety and efficacy of ABT-122 given with methotrexate in subjects with active rheumatoid arthritis who have an inadequate response to methotrexate

ID: NCT02141997 (<https://clinicaltrials.gov/ct2/show/NCT02141997>)

Phase: Phase 2

Status: Completed

コメント : ABT-122 は TNF α と IL-17 を中和する bispecific antibody.

Adalimumab 40mg/2 週と比較して, ABT-122 120mg/2 週は ACR20 で同等の効果を示し, ABT-122 120mg/週ではより効果が高い傾向があった. Safety profile は全ての群で差を認めなかった

(<http://acrabstracts.org/abstract/abt-122-a-tnf-and-il-17-targeted-dual-variable-domain-dvd-ig-in-rheumatoid-arthritis-patients-with-inadequate-response-to-methotrexate-results-from-a-phase-2-trial/>).